课题基金 / 基金详情

COVID-19 Variant Supplement - Towards anti-COVID-19 therapeutic development by targeting the viral papain-like proteinase

COVID-19 Variant Supplement - Towards anti-COVID-19 therapeutic development by targeting the viral papain-like proteinase
COVID-19 变异补充剂 - 通过靶向病毒木瓜蛋白酶样蛋白酶来开发抗 COVID-19 疗法
批准号：
443281
负责人：
James Michael N
金额：
$3.64万
依托单位：
University of Alberta
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-02-01 至 2022-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=443281&lang=en
关键词：
Inhibitor Design For The Papain-Like Enzyme Form Covid-19

项目摘要

项目成果

James Michael N的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
When positive-stranded RNA viruses such as the causative agent for the 2019-2020 novel coronavirus (SARS-CoV-2) outbreak enter an infectious cycle in the cell, their RNA genomes hijack the host cell's protein production machinery to mass produce large con
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Towards anti-COVID-19 therapeutic development by targeting the viral papain-like proteinase
  • 批准号：
    422703
  • 项目类别：
    Operating Grants
  • 资助金额：
    $18.13万
  • 财政年份：
    2020
  • 负责人：
    James Michael N
  • 依托单位：
    University of Alberta
Mucopolysaccharidosis I Disease: Tools for Discovery and Design of Chaperone Therapeutics Based on Unique Enzyme Production Systems and the Elucidation of the Structure of alpha-L-Iduronidase
  • 批准号：
    252123
  • 项目类别：
    Operating Grants
  • 资助金额：
    $28.24万
  • 财政年份：
    2012
  • 负责人：
    James Michael N
  • 依托单位：
    University of Alberta